Baidu
map

JACC:家族性高胆固醇血症基因检测共识:仅根据LDL-C升高判断,会漏诊相当一部分患者

2018-08-21 钟巧青 高磊 中国循环杂志

近期,家族性高胆固醇血症(FH)专家组在JACC杂志发表了关于家族性高脂蛋白血症基因检测的科学声明,以下是该文的十大要点,值得临床工作者关注。

近期,家族性高胆固醇血症(FH)专家组在JACC杂志发表了关于家族性高脂蛋白血症基因检测的科学声明,以下是该文的十大要点,值得临床工作者关注。

1、FH是一种相对常见的遗传性疾病,这类疾病的患者因长期的LDL-C升高而导致过早发生动脉粥样硬化性血管疾病(ASCVD)。

2、FH基因检测有望促进FH的诊断,以便尽早启动强化降脂治疗,进而辨识FH患者家族中未被发现的FH家庭成员,并积极干预,从而减轻FH家族中的血管病(CVD)负担。

3、未治疗的男性FH患者在50岁以前发生致死性或非致死性性血管事件的风险高达50%,而未治疗的女性FH患者在60岁以前发生致死性或非致死性性血管事件的风险达30%。

4、 FH包括一系列的临床表型和多种不同的致病基因变异。其中纯合子家族性高脂白血症最为罕见,FH的患者血液中Lp(a)的浓度明显升高。特定类型的致病基因的变异和严重性与高胆固醇血症的严重程度、发生冠心病的风险以及早发冠心病的风险有关,致病基因的变异是 LDL-C 治疗目标的独立预测因子。

5、FH的临床表型包括异常升高的LDL-C、早发CVD的家族史、高胆固醇血症家族史或冠心病家族史、全身相关部位出现肌腱黄瘤、眼角膜周围出现白斑等,但仅凭上述这些指标来诊断FH的敏感性很低。因此DNA检测出明确致病基因的变异是确诊FH的必须条件。

6、仅仅根据LDL-C升高的数值来诊断FH,则会漏诊相当一部分基因突变尤其是FH致病基因变异的患者。根据基因诊断为FH的患者中,大约45%的患者LDL-C水平<4.9 mmol/L。

7、基因型阴性或是遗传型阴性而临床表型阳性的FH患者应该考虑是否有其他的分子病因,包括多基因疾病、高 Lp(a)或是其他一些未发现的FH致病基因。FH的基因检测有助于判断预后并能优化和精细判断CAD的危险分层。

8、任何年龄段的患者,根据临床症状、体征结合家族史而高度怀疑为FH,都应该进行基因检测。下列情况均属怀疑对象:

1)儿童LDL-C 水平持续≥ 4.14 mmol/L或者成人LDL-C 持续≥4.91 mmol/L,无任何原因所致的继发性高胆固醇血症,以及有一个以上的一级亲属出现类似情况,或有早发CAD(男性 ≤55岁, 女性 ≤65 岁)或者家族史不能得到(比如被收养)。

2)儿童患者 LDL-C 持续≥4.91 mmol/L或者成人患者 LDL-C 持续 ≥6.47 mmol/L且无其他明显原因导致继发性高胆固醇血症,即便无阳性家族史。

9、对FH的基因测试在下列临床情况下可以考虑:

1)儿童LDL-C持续 ≥ 4.14 mmol/L(无其他原因所致的继发性高胆固醇)有一个及以上的父母LDL-C ≥4.91 mmol/L或者有高胆固醇血症和早发CAD的家族史。

2)成人患者,即使未知晓其治疗前的LDL-C水平,但是有自身的早发CAD的病史和有高胆固醇血症以及早发CAD的家族史。

3)成人LDL-C持续≥4.14 mmol/L(无其他原因所致的继发性高胆固醇血症),如果有高胆固醇血症家族史以及有自身早发CAD或有早发CAD的家族史。

10、对于有确认特殊基因变异的FH先证者的所有一级亲属应该进行级联基因检测。如果没有一级亲属,或一级亲属不愿意接受检测,则建议二级亲属接受已知家族性的变异基因检测。级联基因检测应该扩展到整个家族中进行,直至所有的危险个体得到检测和所有已知亲属中存在的FH得到确认。

原始出处:Sturm AC, Knowles JW, Gidding SS, et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854134, encodeId=028b185413438, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 30 15:08:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325941, encodeId=33291325941cb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380078, encodeId=02e113800e88c, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407363, encodeId=17d6140e3632d, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422571, encodeId=447d14225e1ed, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629538, encodeId=4345162953867, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2019-06-30 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854134, encodeId=028b185413438, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 30 15:08:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325941, encodeId=33291325941cb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380078, encodeId=02e113800e88c, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407363, encodeId=17d6140e3632d, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422571, encodeId=447d14225e1ed, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629538, encodeId=4345162953867, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2018-08-23 智智灵药
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854134, encodeId=028b185413438, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 30 15:08:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325941, encodeId=33291325941cb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380078, encodeId=02e113800e88c, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407363, encodeId=17d6140e3632d, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422571, encodeId=447d14225e1ed, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629538, encodeId=4345162953867, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854134, encodeId=028b185413438, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 30 15:08:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325941, encodeId=33291325941cb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380078, encodeId=02e113800e88c, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407363, encodeId=17d6140e3632d, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422571, encodeId=447d14225e1ed, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629538, encodeId=4345162953867, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854134, encodeId=028b185413438, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 30 15:08:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325941, encodeId=33291325941cb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380078, encodeId=02e113800e88c, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407363, encodeId=17d6140e3632d, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422571, encodeId=447d14225e1ed, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629538, encodeId=4345162953867, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2018-08-23 zhwj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854134, encodeId=028b185413438, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jun 30 15:08:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325941, encodeId=33291325941cb, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380078, encodeId=02e113800e88c, content=<a href='/topic/show?id=bef6102602a9' target=_blank style='color:#2F92EE;'>#高胆固醇血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102602, encryptionId=bef6102602a9, topicName=高胆固醇血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1d1470, createdName=刘阔, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407363, encodeId=17d6140e3632d, content=<a href='/topic/show?id=144966640f8' target=_blank style='color:#2F92EE;'>#漏诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66640, encryptionId=144966640f8, topicName=漏诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d362645427, createdName=makuansheng, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422571, encodeId=447d14225e1ed, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629538, encodeId=4345162953867, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Thu Aug 23 08:08:00 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2018-08-23 wetgdt

相关资讯

JAMA Cardiol:全新血脂Meta分析支持LDL-C“越低越好”,临床获益来自降脂本身

Marc Sabatine等在JAMA心脏病子刊的一项Meta分析显示,对于低密度脂蛋白胆固醇(LDL-C)已经很低(70 mg/dl以下)的患者,使LDL-C进一步降低,患者的心血管风险仍可进一步降低。

Circulation:空腹和非空腹低密度脂蛋白胆固醇检查准确度哪个高?

由此可见,对于非空腹标本,新调整的LDL-C估算法性能要优于Friedewald估算法,在低LDL-C和高甘油三酯的人群中,具有特定的准确度优势。除了促进进一步的研究外,这些结果可能对指南委员会、实验室带头人、临床医生和病人具有直接的指导价值。

AHA 2017:重要实验结果公布:Anacetrapib对新发糖尿病发病及糖尿病患者血管事件的影响

众所周知,糖尿病患者的心血管发病及死亡风险会增加,而采用他汀治疗降低LDL-C可使糖尿病的发病风险增加10%~20%。

JACC:低密度脂蛋白胆固醇处于正常水平就安全了?

传统上认为,缺乏心血管危险因素(CVRFs)患动脉粥样硬化的风险低,然而,没有CVRFs的个体仍报道有不良心血管事件的发生。本研究的目的旨在评估分析没有CVRF的个体患亚临床动脉粥样硬化的危险预测因素。本研究纳入了PESA临床试验中无传统心血管危险因素的个体(n = 1,779; 平均年龄为45.0 ± 4.1 岁,女性占 50.3%)。无传统心血管危险因素包括一下几点:不吸烟,血压<140/90

Hypertension:中心和肱动脉血压、他汀类药物和LDL-C相关性分析!

总之,LDL-C降低只与他汀类使用者血压降低的一小部分有关,并且似乎主要与舒张压的改善有关,而非LDL-C介导的途径大多与脉压成分的变化有关。

Circulation:炎症是否会影响evolocumab降低LDL-C和心血管意外风险的效果?

FOURIER试验发现PCSK9(9型前体蛋白转化酶枯草杆菌蛋白酶/kexin)抑制剂evolocumab可降低低密度脂蛋白(LDL-C)和心血管意外风险。但是,evolocumab的疗效是否受基础炎症风险影响,尚未明确。Erin A. Bohula等人以基线高敏的C反应蛋白(hsCRP)将FOURIER试验的受试者分层来研究evolocumab的疗效。本试验共纳入27564位采用一种他汀类药物治

Baidu
map
Baidu
map
Baidu
map